Filing Details

Accession Number:
0001140361-23-038432
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-08-07 21:30:35
Reporting Period:
2023-08-03
Accepted Time:
2023-08-07 21:30:35
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1635088 Roivant Sciences Ltd. ROIV Pharmaceutical Preparations (2834) 981173944
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1801917 Eric Venker C/O Roivant Sciences Ltd.
7Th Floor, 50 Broadway
London X0 SW1H 0DB
Chief Operating Officer No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Shares Acquisiton 2023-08-03 44,629 $3.85 672,547 No 4 M Direct
Common Shares Disposition 2023-08-03 44,629 $11.93 627,918 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Shares Stock Option (Right to Buy) Disposition 2023-08-03 44,629 $0.00 44,629 $3.85
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
14,583,389 2032-04-19 No 4 M Direct
Footnotes
  1. The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (1) to this Form 4. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2023.
  2. Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the applicable vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation).